Novel benzyl substituted titanocene anti-cancer drugs

被引：119
|
作者：
Sweeney, NJ [1 ]
Mendoza, O [1 ]
Müller-Bunz, H [1 ]
Pampillón, C [1 ]
Rehmann, FJK [1 ]
Strohfeldt, K [1 ]
Tacke, M [1 ]
机构：
[1] Univ Coll Dublin, Ctr Synth Chem Biol, Dept Chem, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland
来源：
JOURNAL OF ORGANOMETALLIC CHEMISTRY | 2005年 / 690卷 / 21-22期
基金：
爱尔兰科学基金会;
关键词：
anti-cancer drug; cis-platin; titanocene; fulvene; super hydride; LLC-PK;
D O I：
10.1016/j.jorganchem.2005.06.039
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
From the novel reaction of Super Hydride (LiB(Et)(3)H) with 6-(p-NN-dimethylanilinyl)fulvene (1a) or 6-(p-methoxyphenyl)fulvene (1b) the corresponding lithium cyclopentadienide intermediates (2a, 2b) were obtained. When reacted with TiCl4, bis-[(P-dimethylaminobenzyl)cyclopentadienyl]titanium (IV) dichloride (3a) and bis-[(p-methoxybenzyl)cyclopentadienyl]titanium (IV) dichloride (3b) were obtained. Titanocene 3a was reacted with an ethereal solution of HCl, by which its dihydrochloride derivative (3c) was formed and isolated. Titanocenes 3b and 3c were characterised by X-ray crystallography. When the titanocenes 3a-c were tested against pig kidney carcinoma (LLC-PK) cells inhibitory concentrations (IC50) of 1.2 x 10(-4) M, 2.1 x 10(-5) M and 9.0 X 10(-5) M, respectively, were observed. These values represent improved cytotoxicity against LLC-PK, most notably for 3b (Titanocene Y), which is a hundred times more cytotoxic than titanocene dichloride itself. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码：4537 / 4544
页数：8
相关论文
共 50 条
  • [11] Synthesis and cytotoxicity studies of new dimethylamino-functionalised and hetero aryl-substituted titanocene anti-cancer drugs
    Pampillon, Clara
    Sweeney, Nigel J.
    Strohfeldt, Katja
    Tacke, Matthias
    [J]. JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2007, 692 (11) : 2153 - 2159
  • [12] Diarylmethyl substituted titanocenes:: Promising anti-cancer drugs
    Pampillon, Clara
    Mendoza, Oscar
    Sweeney, Nigel J.
    Strohfeldt, Katja
    Tacke, Matthias
    [J]. POLYHEDRON, 2006, 25 (10) : 2101 - 2108
  • [13] Heteroaryl substituted titanocenes as potential anti-cancer drugs
    Sweeney, Nigel
    Gallagher, William M.
    Mueller-Bunz, Helge
    Pampillon, Clara
    Strohfeldt, Katja
    Tacke, Matthias
    [J]. JOURNAL OF INORGANIC BIOCHEMISTRY, 2006, 100 (09) : 1479 - 1486
  • [14] Substituted ajoenes as novel anti-cancer agents
    Hunter, Roger
    Kaschula, Catherine H.
    Parker, Iqbal M.
    Caira, Mino R.
    Richards, Philip
    Travis, Susan
    Taute, Francois
    Qwebani, Thozama
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (19) : 5277 - 5279
  • [15] Novel anti-cancer drugs and therapeutic approaches
    Bergmann-Leitner, E
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (03) : 259 - 260
  • [16] Anti-cancer drugs
    Bergmann-Leitner, ES
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (09) : 1077 - 1078
  • [17] Anti-cancer drugs
    Bergmann-Leitner, Elke
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (11) : 1048 - 1048
  • [18] Anti-Cancer Drugs
    Bergmann-Leitner, Elke
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (07) : 730 - 731
  • [19] Benzyl-substituted titanocene dichloride anticancer drugs: From lead to hit
    Claffey, James
    Mueller-Bunz, Helge
    Tacke, Matthias
    [J]. JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2010, 695 (18) : 2105 - 2117
  • [20] The novel approaches for the development of anti-cancer drugs - Preface
    Bergmann-Leitner, ES
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (16) : U2 - U3
12345